Sant Pau - Institut de Recerca

Principales líneas de investigación

Proyectos sanitarios.
Estudios de mecanismos patogénicos que alteran la distribución de grasa corporal.
Estudio de trastornos metabólicos asociados al tratamiento antirretroviral.
Cambios en la composición corporal.
Nuevos fármacos antirretrovirales.
Riesgo cardiovascular asociado al tratamiento antirretroviral.
Condiciones de comorbilidad asociadas a la infección por VIH-1.
Farmacogenética (toxicocinética).
Meningitis bacteriana.

Retos

Proyectos sanitarios

Continuidad, expansión y consolidación del equipo de atención de pacientes infectados con VIH-1, que actualmente consiste en 3 médicos, 4 investigadores asociados subvencionados (incluyendo un investigador Río Hortega) y 2 enfermeras.
Continuidad en la participación en proyectos multicéntricos (especialmente en la red SIDA, Gesida, Vacher, EuroSIDA y colaboración ART).
Exploración de posibles participaciones en ensayos clínicos con nuevos fármacos antirretrovirales.
Incrementar el número de pacientes con VIH-1 que hacen seguimiento a nuestro Hospital (dada la actual tasa de mortalidad, se requiere un incremento anual de 50 pacientes).
Continuidad con los ensayos clínicos en desarrollo actualmente y con las líneas de investigación clínica básicas.

Mecanismos patogénicos que alteran la distribución de grasa corporal

Estudio del metabolismo en pirimidinas y derivados en la génesis de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.
Desarrollo de un modelo animal (ratón) para lipodistrofia.
Desarrollo de modelos in vitro (cultivos de adipocitos) para estudiar la toxicidad adiposa de los fármacos antirretrovirales.
Estudio de las nuevas manifestaciones del síndrome de lipodistrofia.
Desarrollo de medidas para la concentración de fármacos antirretrovirales en el tejido adiposo.
Exploración del rol de la inflamación en la patogénesis de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.
Metabolismo de la uridina y su rol en la patogénesis de la lipodistrofia.

Trastornos metabólicos asociados al tratamiento antiretroviral

Valoración in vivo de la toxicidad metabólica asociada al tratamiento antirretroviral.
Desarrollo de modelos in vitro (cultivos de adipocitos) para estudiar la toxicidad adiposa de los fármacos antirretrovirales.
Estudio de los factores que contribuyen a la esteatosis hepática en pacientes con tratamiento antirretroviral.
Estudio del rol patogénico del FGF21 en la resistencia a la insulina en pacientes con VIH-1.
Estudio del rol de FABP4 en trastornos metabólicos asociados al tratamiento antirretroviral.

Composición corporal

Definición de la distribución normal de grasa en la población general.
Establecer patrones de distribución anormal de grasa.
Desarrollo de una definición de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.

Nuevos fármacos antiretrovirales

Ensayos clínicos de nuevos fármacos antirretrovirales (fase II y III).
Potenciación farmacocinética de ritonavir y no ritonavir en fármacos antirretrovirales.

Riesgo cardiovascular asociado al tratamiento antiretroviral

Establecimiento de una cohorte de riesgo cardiovascular multicentro.
Estudio de factores dependientes de tratamiento antirretroviral y no dependientes en cohortes multicentro.
Desarrollo de modelos in vitro (cultivos de adipocitos para estudiar la toxicidad adiposa de los fármacos antirretrovirales.

Condiciones de comorbilidad asociadas a la infección por VIH-1

Estudio del envejecimiento en diferentes tejidos asociados a la infección por VIH-1 y tratamientos antirretrovirales.
Estudio de la fragilidad en pacientes con infección por VIH-1 y el rol de HAART.
Evaluación de la función neurocognitiva en pacientes con infección por VIH-1 con y sin tratamiento antirretroviral.
Participación en estudios multicéntricos de cohorte para determinar la incidencia de comorbilidades específicas (cáncer, hepatitis C, enfermedad cardiovascular, osteogénesis / osteoporosis): EuroSIDA, Colaboración ARTE, Gesida, Vacher, etc.
Tratamiento de la hepatitis C en pacientes con VIH-1 y su pronóstico.

Farmacogenética (toxicocinética)

Rol del polimorfismo enzimático de las rutas de la pirimidina en la patogénesis de lipodistrofia.
Rol del polimorfismo enzimático de las rutas de la pirimidina en la patogénesis de toxicidad clínica (neuropatías, pancreatitis).
Rol del polimorfismo de IL28B en cuidado espontánea de hepatitis C como respuesta a tratamientos antirretrovirales basados en interferón y Ribavirin.

Meningitis bacteriana

Identificación de factores de pronóstico en meningitis bacteriana adulta.
Comunicación con un estudio de cohorte de meningitis bacteriana adulta.
Identificación de factores de huésped intrínseco en la patogénesis y prognosis de meningitis bacteriana adulta y enfermedad meningococal.

Coordinación del grupo

DOMINGO PEDROL, PERE FGS
pdomingo@santpau.cat

Miembros

Herrera Bachs, Silvia IR

Millan Revilla, Lucia IR

Muñoz Rodriguez, Jessica IR

Publicaciones 2024

(JIF 2024)

-Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez MA, López JC, Pinto A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S, CoRIS C. Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV. JOURNAL OF INFECTIOUS DISEASES. 2024; 230(2). DOI:10.1093/infdis/jiae168. PMID:38557859. IF:4,500 (Q1/2D). Document type: Article.

-Castellá M, Mestres A, Gavaldà A, Blasco A, Quesada T, Romero I, Giralt M, Villarroya F, Cereijo R. The splicing factor SF3B1 is involved in brown adipocyte thermogenic activation. BIOCHEMICAL PHARMACOLOGY. 2024; 220:116014. DOI:10.1016/j.bcp.2023.116014. PMID:38158020. IF:5,600 (Q1/1D). Document type: Article.

-de Lazzari E, Negredo EB, Domingo P, Tiraboschi JM, Ribera E, Abdulghani N, Alba V, Fernández S, Viladés C, Peraire J, Gatell JM, Blanco JL, Vidal F, Rull A, Martinez E, DOLAM GRP. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(5). DOI:10.1093/jac/dkae083. PMID:38546974. IF:3,600 (Q2/3D). Document type: Article.

-Grunden N, Calabria M, García C, Pons C, Arroyo JA, Gómez B, Estévez MD, Belvís R, Morollón N, Cordero M, Mur I, Pomar V, Domingo P. Evolving trends in neuropsychological profiles of post COVID-19 condition: A 1-year follow-up in individuals with cognitive complaints. PLoS One. 2024; 19(8):e0302415. DOI:10.1371/journal.pone.0302415. PMID:39116061. IF:2,600 (Q2/4D). Document type: Article.

-Nomah DK, Díaz Y, Bruguera A, Moreno S, Aceiton J, Reyes J, Llibre JM, Falcó V, Imaz A, Fanjul FJ, Peraire J, Deig E, Domingo P, Inciarte A, Casabona J, Miró JM, Populational HIV Cohort C. Disparities in Coronavirus Disease 2019 Clinical Outcomes and Vaccination Coverage Among Migrants With Human Immunodeficiency Virus in the PISCIS Cohort: A Population-Based Propensity Score-Matched Analysis. Open Forum Infectious Diseases. 2024; 11(1):ofad693. DOI:10.1093/ofid/ofad693. PMID:38221982. IF:3,800 (Q1/3D). Document type: Article.

-Nomah DK, Jamarkattel S, Bruguera A, Moreno S, Díaz Y, Alonso L, Aceitón J, Llibre JM, Domingo P, Saumoy M, Homar F, Fanjul F, Navarro J, de la Mora L, Knobel H, Orti A, Martin R, Miró JM, Casabona J, Reyes J, PISCIS Cohort Study GRP. Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020. Open Forum Infectious Diseases. 2024; 11(4):ofae132. DOI:10.1093/ofid/ofae132. PMID:38560603. IF:3,800 (Q1/3D). Document type: Article.

-Pan Y-H, Nomah DK, Montoro M, Moreno S, Díaz Y, Aceitón J, Bruguera A, Llibre JM, Domingo P, Imaz A, Vilaró I, Falcó V, Reyes J, Miro JM, Casabona J, the PISCIS Cohort Study G. The impact of the COVID-19 pandemic on healthcare services utilization among people living with HIV in Catalonia, Spain: A population-based cohort study. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2024; 42(10). DOI:10.1016/j.eimc.2023.09.001. PMID:38218704. IF:2,500 (Q2/5D). Document type: Article.

-Quesada T, Cereijo R, Blasco A, Mestres A, Prieto P, Domingo JC, Villarroya F, Domingo P, Giralt M. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. BIOCHEMICAL PHARMACOLOGY. 2024; 220:116010. DOI:10.1016/j.bcp.2023.116010. PMID:38154544. IF:5,600 (Q1/1D). Document type: Article.

-Suades R, Greco MF, Padró T, de Santisteban V, Domingo P, Benincasa G, Napoli C, Greco S, Madè A, Ranucci M, Devaux Y, Martelli F, Badimon L. Blood CD45⁺/CD3⁺ lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; DOI:10.1111/eci.14354. PMID:39548690. IF:3,600 (Q1/2D). Document type: Article.

-Suades R, Greco MF, Prieto P, Padro T, Devaux Y, Domingo P, Badimon L. CD66b⁺/CD68⁺ circulating extracellular vesicles, lactate dehydrogenase and neutrophil-to-lymphocyte ratio can differentiate coronavirus disease 2019 severity during and after infection. Journal of Extracellular Vesicles. 2024; 13(7):e12456. DOI:10.1002/jev2.12456. PMID:39007437. IF:14,500 (Q1/1D). Document type: Article.

Publicaciones 2023

(JIF 2023)

-Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez MA, Roca C, González J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES. 2023; 76(6). DOI:10.1093/cid/ciac880. PMID:36345912. IF:8,200 (Q1/1D). Document type: Article.

-Bruguera A, Nomah D, Moreno S, Diaz Y, Aceiton J, Reyes J, Ambrosioni J, Llibre JM, Falco V, Imaz A, Fanjul F, Navarro G, Pere D, Leon E, Mera A, Miro JM, Casabona J, PISCIS GRP. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023; 52(4):e241-e252. DOI:10.1093/ije/dyad083. PMID:37403345. IF:6,400 (Q1/1D). Document type: Article.

-Castella M, Blasco A, Peyrou M, Gavalda A, Villarroya J, Quesada T, Lorente L, Sancho J, Szymczak F, Piron A, Rodriguez S, Carobbio S, Goday A, Domingo P, Vidal A, Giralt M, Eizirik DL, Villarroya F, Cereijo R. Adipose tissue plasticity in pheochromocytoma patients suggests a role of the splicing machinery in human adipose browning. iScience. 2023; 26(6):106847. DOI:10.1016/j.isci.2023.106847. PMID:37250773. IF:4,600 (Q1/2D). Document type: Article.

-Díaz M, Casano P, Quesada T, López A, de Zegher F, Villarroya F, Ibáñez L. Circulating exosomes decrease in size and increase in number between birth and age 7: relations to fetal growth and liver fat. Frontiers in Endocrinology. 2023; 14:1257768. DOI:10.3389/fendo.2023.1257768. PMID:38027180. IF:3,900 (Q2/3D). Document type: Article.

-Diaz M, Mestres A, Lerin C, Cereijo R, Lopez A, de Zegher F, Villarroya F, Ibanez L. Circulating progranulin in human infants: relation to prenatal growth and early postnatal nutrition. PEDIATRIC RESEARCH. 2023; 94(3). DOI:10.1038/s41390-023-02595-1. PMID:37031297. IF:3,100 (Q1/2D). Document type: Article.

-Garcia C, Navarro A, Lopez A, Quesada T, de Zegher F, Ibanez L, Villarroya F. Meteorin-like levels are associated with active brown adipose tissue in early infancy. Frontiers in Endocrinology. 2023; 14:1136245. DOI:10.3389/fendo.2023.1136245. PMID:36936161. IF:3,900 (Q2/3D). Document type: Article.

-González A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E, NEAT Study Group 022. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2023; 78(9). DOI:10.1093/jac/dkad247. PMID:37539492. IF:3,900 (Q1/3D). Document type: Article.

-Martín R, Pericas C, Bruguera A, Rosell G, Martínez E, Díaz Y, Alonso L, Nomah DK, Blanco JL, Domingo P, Alvarez P, Linares MS, Laborda CV, Mera A, Isbert SC, Johansen IS, Miró JM, Casabona J, Llibre JM, PISCIS GRP. Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study. Microorganisms. 2023; 11(11):2701. DOI:10.3390/microorganisms11112701. PMID:38004713. IF:4,100 (Q2/4D). Document type: Article.

-Martín R, Vazquez MC, Burgos J, Bruguera A, Reyes J, Moreno S, Aceitón J, Díaz Y, Domingo P, Saumoy M, Knobel H, Dalmau D, Borjabad B, Johansen IS, Miro JM, Casabona J, Llibre JM, PISCIS G. Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. Frontiers in Medicine. 2023; 10:1182359. DOI:10.3389/fmed.2023.1182359. PMID:37415770. IF:3,100 (Q1/2D). Document type: Article.

-Palacio J, Moreno S, Díaz Y, Aceitón J, Bruguera A, Nomah DK, Llibre JM, Knobel H, Chivite I, Miro JM, Domingo P, Suanzes P, Fanjul F, Navarro G, Macorigh L, Mera A, Casabona J, Imaz A, Reyes J, ISCIS GRP. Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort. HIV MEDICINE. 2023; 24(9). DOI:10.1111/hiv.13486. PMID:36990962. IF:2,800 (Q2/5D). Document type: Article.

-Pomar V, Benito N, Duch P, Colome M, Rivera A, Domingo P. Acute Bacterial Meningitis in Healthy Adult Patients: A Prospective Cohort Study. Journal of Clinical Medicine. 2023; 12(11):3624. DOI:10.3390/jcm12113624. PMID:37297818. IF:3,000 (Q1/2D). Document type: Article.

-Santos JR, Casadellà M, Noguera M, Micán R, Domingo P, Antela A, Portilla J, Sanz J, Montero M, Navarro J, Masiá M, Valcarce N, Ocampo A, Pérez L, García C, Vivancos MJ, Imaz A, Iribarren JA, Hernández J, Villar J, Barrufet P, Paredes R, INSTINCT GRP. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study. Frontiers in Cellular and Infection Microbiology. 2023; 13:1187999. DOI:10.3389/fcimb.2023.1187999. PMID:37434782. IF:4,600 (Q1/3D). Document type: Article.

-Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce N, Payeras A, Bernal E, Montero M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R, Study 2DGRP. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes. Open Forum Infectious Diseases. 2023; 10(11):ofad542. DOI:10.1093/ofid/ofad542. PMID:38023553. IF:3,800 (Q2/3D). Document type: Article.

-Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz V, Peñafiel J, Tiraboschi J, Morenilla S, Garcia B, Soriano I, Podzamczer D, Imaz A. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. JOURNAL OF INFECTIOUS DISEASES. 2023; 228(7). DOI:10.1093/infdis/jiad304. PMID:37526315. IF:5,000 (Q1/2D). Document type: Article.

-Sempere A, Assoumou L, Gonzalez A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masia M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martinez E, NEAT 022GRP. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus (HIV) at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. CLINICAL INFECTIOUS DISEASES. 2023; 77(7). DOI:10.1093/cid/ciad297. PMID:37207617. IF:8,200 (Q1/1D). Document type: Article.

-Waters L, Assoumou L, Gonzalez A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masia M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martinez E, NEAT 022GRP. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5). DOI:10.1093/cid/ciac827. PMID:36259527. IF:8,200 (Q1/1D). Document type: Article.

Publicaciones 2022

(JIF 2022)

Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13212. PMID:34882940. IF:3 (Q3/7D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
Calvet J, Berenguer A, Gay M, Massanella M, Domingo P, Llop M, Sanchez E, Arevalo M, Carrillo J, Albinana N, Arauz G, Orellana C, Delgado JF, Serrano A, Llobell A, Graell E, Garcia M, Moreno M, Galisteo C, Casado E, Navarro N, Gomez A, Garcia S, Rusinol M, Costa E, Clotet B, Vilaseca M, Blanco J, Gratacos J. Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports. 2022; 12(1):640. DOI:10.1038/s41598-021-04683-w. PMID:35022497. IF:4,6 (Q2/3D). Document type: Article.
Castellvi I, Castillo D, Corominas H, Mariscal A, Orozco S, Benito N, Pomar V, Baucells A, Mur I, de la Rosa D, Lobo D, Millan AM, de Sosa NH, Filella D, Matas L, Martinez L, Juarez C, Casademont J, Domingo P. Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study. Frontiers in Medicine. 2022; 9:973918. DOI:10.3389/fmed.2022.973918. PMID:36004366. IF:3,9 (Q2/4D). Document type: Article.
Castro A, Diaz P, Domingo P, Garcia C, Losa JE, Castro A, Vidal N, Aceituno S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6). DOI:10.7399/fh.13038. PMID:36520571. Document type: Article.
Collazos J, Domingo P, Fernandez N, Asensi E, Vilchez H, Lalueza A, Roy E, Blanes R, Raya M, Sanz J, Artero A, Ramos JM, Duenas C, Lamas JL, Asensi V, Valproic Acid COVID GRP. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022; 17(1):e0262777. DOI:10.1371/journal.pone.0262777. PMID:35085321. IF:3,7 (Q2/4D). Document type: Article.
Cozzi A, Peters L, Pelchen A, Neesgaard B, Stephan C, Elbirt D, Brännström J, Paduta D, Trofimova T, Szlavik J, Van V, Pai H, Lundgren J, Harxhi A, Losso M, Kundro M, Schmied B, Karpov I, Vassilenko A, Paduto D, Mitsura VM, Clumeck N, De Wit S, Delforge M, Hadziosmanovic V, Begovac J, Machala L, Jilich D, Gerstoft J, Pedersen C, Sedlacek D, et al. [Domingo P], for the EuroSIDA Study Group. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy. 2022; 19(1):38. DOI:10.1186/s12981-022-00457-0. PMID:35933352. IF:2,2 (Q4/8D). Document type: Article.
De Dios A, Masip M, Pagès N, Riera P, Mateo MG, Del Mar M, Mangues MA, Gomis M. Desarrollo de una intervención mHealth para rediseñar la ruta asistencial de las personas que viven con VIH: Estudio cualitativo. Farmacia Hospitalaria. 2022; 46. DOI:10.7399/fh.13249. PMID:36520560. Document type: Article.
Domingo P, Giralt M, Gavalda A, Blasco A, Delgado A, Gallego JM, Gutierrez MD, Mateo MG, Cereijo R, Domingo JC, Villarroya F, Villarroya J. Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy. 2022; 11(1):2042962. DOI:10.1080/21623945.2022.2042962. PMID:35300561. IF:3,3 (Q3/6D). Document type: Article.
Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderros L, Gallego JM, Gutierrez MD, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine. 2022; 11(3):549. DOI:10.3390/jcm11030549. PMID:35160008. IF:3,9 (Q2/4D). Document type: Article.
Domingo P, Quesada T, Villarroya J, Cairo M, Gutierrez MD, Mateo MG, Mur I, Corbacho N, Domingo JC, Villarroya F, Giralt M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308:120948. DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6,1 (Q1/2D). Document type: Article.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Tellez MJ, Dominguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero A, Santos I, Giner L, Arminanzas C, Montero M, Manzardo C, Cifuentes C, Garcia C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodriguez C, Gaspar G, Perez L, Losa JE, Force L, Veloso S, Martinez E, Jarrin I, De Miguel M, Garcia JG. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV MEDICINE. 2022; 23(7). DOI:10.1111/hiv.13229. PMID:35037379. IF:3 (Q3/7D). Document type: Article.
Franquet T, Domingo P. Pulmonary Infections in People Living with HIV. RADIOLOGIC CLINICS OF NORTH AMERICA. 2022; 60(3). DOI:10.1016/j.rcl.2022.01.008. PMID:35534134. IF:1,9 (Q3/8D). Document type: Review.
Franquet T, Gimenez A, Ketai L, Mazzini S, Rial A, Pomar V, Domingo P. Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. EUROPEAN RADIOLOGY. 2022; 32(7). DOI:10.1007/s00330-022-08580-2. PMID:35226158. IF:5,9 (Q1/2D). Document type: Article.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:2,5 (Q3/6D). Document type: Article.
Garcia C, Cereijo R, Plou C, Gavalda A, Malpique R, Villarroya J, Lopez A, de Zegher F, Ibanez L, Villarroya F. Posterior Cervical Brown Fat and CXCL14 Levels in the First Year of Life: Sex Differences and Association With Adiposity. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022; 107(3). DOI:10.1210/clinem/dgab761. PMID:34677618. IF:5,8 (Q1/3D). Document type: Article.
Garreta E, Prado P, Stanifer ML, Monteil V, Marco A, Ullate A, Moya D, Vilas A, Tarantino C, Romero JP, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo M, González F, Domingo P, Gavaldà A, del Pozo CH, Hasan O, Ventura P, Campistol JM, Prosper F, Mirazimi A, Boulant S, Penninger JM, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabolism. 2022; 34(6). DOI:10.1016/j.cmet.2022.04.009. PMID:35561674. IF:29 (Q1/1D). Document type: Article.
Gavalda A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: An update on actors and actions. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2022; 23(1). DOI:10.1007/s11154-021-09640-6. PMID:33712997. IF:8,2 (Q1/1D). Document type: Review.
Llaurado G, Vlacho B, Wargny M, Ruan Y, Franch J, Domingo P, Gourdy P, Saulnier PJ, Hadjadj S, Wild SH, Rea R, Cariou B, Khunti K, Mauricio D. The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19). Cardiovascular Diabetology. 2022; 21(1):216. DOI:10.1186/s12933-022-01657-8. PMID:36261811. IF:9,3 (Q1/1D). Document type: Article.
Martin R, Reyes J, Bruguera A, Aceitón J, Díaz Y, Moreno S, Domingo P, Burgos J, Tiraboschi JM, Johansen IS, Álvarez H, Miró JM, Casabona J, Llibre JM, PISCIS G. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. Eclinicalmedicine. 2022; 52:101600. DOI:10.1016/j.eclinm.2022.101600. PMID:35958520. IF:15,1 (Q1/1D). Document type: Article.
Masip J, Jorba R, Lopez M, Domingo P, Pacheco YM, Garcia G, Martinez E, Vilades C, Veloso S, Alba V, Olona M, Vidal F, Gomez F, Peraire J, Rull A. Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(15):8071. DOI:10.3390/ijms23158071. PMID:35897644. IF:5,6 (Q1/3D). Document type: Article.
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Foppa CU, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13210. PMID:34889022. IF:3 (Q3/7D). Document type: Article.
Moga E, Lynton E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology. 2022; 13:904686. DOI:10.3389/fimmu.2022.904686. PMID:35833134. IF:7,3 (Q1/3D). Document type: Review.
Munoz J, Millan L. The role of nurses in the prevention of anal cancer in HIV- infected men having sex with men – a focus on papillomavirus vaccination and anal cytology screening. AIDS REVIEWS. 2022; 24(4). DOI:10.24875/AIDSRev.M22000053. PMID:36580603. IF:2,2 (Q4/8D). Document type: Review.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM, PISCIS GRP. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(8). DOI:10.1093/jac/dkac177. PMID:35678461. IF:5,2 (Q1/2D). Document type: Article.
Podzamczer D, Mican R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masia M, Gomez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro A, Bernal E, Vinuesa D, Knobel H, Troya J, Macias J, Montero M, Sanz J, Navarro A, Caicedo A, Fernandez G, Martinez E, Moreno S, SYMTRI I. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3):ofab595. DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4,2 (Q2/4D). Document type: Article.
Reyes D, Lopez J, Moga E, Pla F, Lynton E, Rojas R, Turon J, Querol L, Olive M, Alvarez R, Caballero M, Carbayo A, Vesperinas A, Domingo P, Illa I, Gallardo E, Cortes E. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(4):e200002. DOI:10.1212/NXI.0000000000200002. PMID:35728947. IF:8,8 (Q1/1D). Document type: Article.
Riancho JA, Peris P, González J, Pérez JL, Cannata J, Cano A, Carbonell C, Casado E, Ciria M, Corral L, del Pino J, Del Río LM, Díaz M, Díez A, García A, Gómez C, Gómez de Tejada Romero MJ, Guañabens N, Hawkins F, Jódar E, Malouf J, Martínez Díaz G, Monegal A, Muñoz M, Naves M, Nogues X, Nolla JM, Olmos JM, Peris P, Quesada JM, Rodríguez M, Sosa M, Torrijos A, Valero Díaz de Lamadrid C, SEIOMM Osteoporosis Guidelines Writing G. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1). DOI:10.4321/S1889-836X2022000100002. Document type: Article.
Saumoy M, Sanchez JL, Assoumou L, Gatell JM, Gonzalez A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masia M, Ordonez J, Pozniak A, Martinez E, Podzamczer D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(7). DOI:10.1093/jac/dkac117. PMID:35411401. IF:5,2 (Q1/2D). Document type: Article/Practice guideline.
Spinner CD, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, Stephan CJ, DeGrosky M, Bainbridge V, Zhan J, Dumitrescu TP, Jeffrey JL, Xu JF, Halliday F, Gan JJ, Johnson M, Gartland M, Joshi SR, Lataillade M, Study 208132. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. CLINICAL INFECTIOUS DISEASES. 2022; 75(5). DOI:10.1093/cid/ciab1065. PMID:34996113. IF:11,8 (Q1/1D). Document type: Article.
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6). DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:16,1 (Q1/1D). Document type: Article.
Yeregui E, Masip J, Vilades C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, Garcia G, Negredo E, Olona M, Vidal J, Peraire M, Marti A, Reverte L, Gomez F, Leal M, Vidal F, Peraire J, Rull A. Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4):2202. DOI:10.3390/ijms23042202. PMID:35216318. IF:5,6 (Q1/3D). Document type: Article.

Publicaciones 2021

Alserawan L, Penacoba P, Echevarria S, Castillo D, Ortiz E, Martinez L, Naranjo EM, Domingo P, Castellvi I, Juarez C, Mariscal A. Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics. 2021; 11(11):1998. DOI:10.3390/diagnostics11111998. PMID:34829345. IF:3,992.
Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jablonowska E, Ostergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A, Group ES. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2021; 86(2). DOI:10.1097/QAI.0000000000002541. PMID:33079903. IF:3,771.
Arroyo JA, Julve J, Vlacho B, Corcoy R, Ponte P, Roman E, Navas E, Llaurado G, Franch J, Domingo P, Mauricio D. Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health. 2021; 9:758347. DOI:10.3389/fpubh.2021.758347. PMID:34631653. IF:6,461.
Berenguer J, Borobia AM, Ryan P, Rodriguez J, Bellon JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Mancebo J, MARTIN A. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. THORAX. 2021; 76(9). DOI:10.1136/thoraxjnl-2020-216001. PMID:33632764. IF:9,102.
Brochado O, Martinez I, Berenguer J, Medrano L, Gonzalez J, Jimenez MA, Carrero A, Hontanon V, Navarro J, Guardiola JM, Fernandez A, Resino S, Domingo P, Esteban H. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. JOURNAL OF BIOMEDICAL SCIENCE. 2021; 28(1):23. DOI:10.1186/s12929-021-00718-6. PMID:33785040. IF:12,771.
Camps A, Perez S, Subirana I, Teira R, Estrada V, Domingo P, Degano IR, Marrugat J. Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population. Journal of Personalized Medicine. 2021; 11(11):1085. DOI:10.3390/jpm11111085. PMID:34834438. IF:3,508.
Cereijo R, Quesada T, Gavalda A, Tarasco J, Pellitero S, Reyes M, Puig M, Giralt M, Sanchez D, Villarroya F. The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans. INTERNATIONAL JOURNAL OF OBESITY. 2021; 45(3). DOI:10.1038/s41366-020-00732-y. PMID:33414488. IF:5,551.
Corbacho N, Mur I, Molas ME, Vidal F, Domingo P. The pharmacological management of cardiovascular disease in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(6). DOI:10.1080/14656566.2020.1856075. PMID:33283570. IF:4,103.
Corominas H, Castellvi I, Diaz C, Matas L, de la Rosa D, Mangues MA, Moya P, Pomar V, Benito N, Moga E, Hernandez N, Casademont J, Domingo P. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. MEDICINE. 2021; 100(19):e25923. DOI:10.1097/MD.0000000000025923. PMID:34106658. IF:1,817.
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF:10,190.
Domingo P, Pomar V, Mur I, Castellvi I, Corominas H, de Benito N. Not all COVID-19 pandemic waves are alike. CLINICAL MICROBIOLOGY AND INFECTION. 2021; 27(7). DOI:10.1016/j.cmi.2021.04.005. PMID:33887469. IF:13,310.
Elias MJP, Alejos B, Gutierrez MM, Crespo M, Gil ID, Ribera E, Galindo MJ, Lozano F, Cifre AP, Boix V, Montero M, Sanz J, Lima JD, Palacios R, Moral SDF, Martinez E. Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(4). DOI:10.1093/jac/dkaa547. PMID:33501995. IF:5,758.
Fernández I, de Lazzari E, Inciarte A, Diaz-Brito V, Milinkovic A, Arenas-Pinto A, Etcheverrry F, García F, Leal L; HIV-PEP Group [Domingo P]. Network meta-analysis of post-exposure prophylaxis randomized clinical trials. HIV Medicine. 2021;22(3):218-224. DOI:10.1111/hiv.12964. PMID: 33108035. IF:3,094.
Gonzalez A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martinez E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9). DOI:10.1093/jac/dkab158. PMID:34120186. IF:5,758.
Grau B, Camprubi D, Marti H, Fernandez M, Carreras C, Velasco M, Ferrer E, Muelas M, Jullien S, Barilaro G, Ajanovic S, Vera I, Moreno L, Gonzalez E, Cortes N, Roldan M, Artes A, Mur I, Domingo P, Garcia F, Guinovart C, Munoz J. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021; 22(1):808. DOI:10.1186/s13063-021-05758-9. PMID:34781981. IF:2,728.
Gutierrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachon J, Carratala J, Berenguer J, Arribas JR, Rodriguez J, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Puig M, Mancebo J, Martinez G. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. LANCET INFECTIOUS DISEASES. 2021; 21(6). DOI:10.1016/S1473-3099(21)00019-0. PMID:33636145. IF:71,421.
Gutierrez MD, Mur I, Mateo MG, Vidal F, Domingo P. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(9). DOI:10.1080/14656566.2021.1887140. PMID:33634724. IF:4,103.
Kowalska JD, Pelchen A, Ryom L, Losso MH, Trofimova T, Mitsura VM, Khromova I, Paduta D, Stephan C, Domingo P, Bakowska E, Monforte AD, Oestergaard L, Jablonowska E, Kuznetsova A, Moreno S, Vasylyev M, Pradier C, Battegay M, Vandekerckhove L, Castagna A, Raben D, Mocroft A, EuroSIDA GRP. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. AIDS. 2021; 35(12). DOI:10.1097/QAD.0000000000002954. PMID:34033590. IF:4,632.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Llibre JM, Domingo P, Falco V, Imaz A, Cortes C, Force L, Letang E, Vilaro I, Casabona J, Miro JM, Mur I, Macorigh L. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11). DOI:10.1016/S2352-3018(21)00240-X. PMID:34655549. IF:16,070.
Ortega E, Corcoy R, Gratacos M, Claramunt FXC, Mata M, Puig R, Real J, Vlacho B, Castelblanco E, Domingo P, Khunti K, Franch J, Mauricio D. Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open. 2021; 11(7):e051237. DOI:10.1136/bmjopen-2021-051237. PMID:34301668. IF:3,006.
Palacio J, Reyes JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaro I, Borras FH, Falco V, Riera M, Domingo P, de Lazzari E, Miro JM, Casabona J, Gurgui M, Hernandez J. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC PUBLIC HEALTH. 2021; 21(1):1596. DOI:10.1186/s12889-021-11613-y. PMID:34454444. IF:4,135.
Reyes M, Gonzalez L, Ibeas K, Cereijo R, Taxeras SD, Pellitero S, Martinez E, Tarasco J, Moreno P, Malagon P, Higueras C, Soria A, Puig M, Villarroya F, Serra D, Herrero L, Sanchez D. White adipose tissue-infiltrated CD11b+myeloid cells are a source of S100A4, a new potential marker of hepatic damage. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2021; 184(4). DOI:10.1530/EJE-20-1130. PMID:33524007. IF:6,558.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martinez E, DOLAM GRP. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8). PMID:34358497. IF:16,070.
Shankar M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez A, Feuth T, Garcia F, Garcia R, Gonzalez I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, et al. [Pomar V, Benito N]. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2021; 326(6). DOI:10.1001/jama.2021.11330. PMID:34228774. IF:157,335.
Teira R, Diaz H, Aragao F, Marguet S, de la Fuente B, Munoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martinez E, Geijo P, Estrada V, Garcia J, Sepulveda MA, Berenguer J. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS One. 2021; 16(4):e0249515. DOI:10.1371/journal.pone.0249515. PMID:33831047. IF:3,752.
Teira R, Diaz H, Aragao F, Munoz J, Galindo P, Merino M, de la Fuente B, Sepulveda MA, Domingo P, Garcia J, Castano M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martinez E, Estrada V, Montero M, Berenguer J, Espinosa N. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research & Clinical Practice. 2021; 22(3). DOI:10.1080/25787489.2021.1955197. PMID:34410219. IF:1,676.
Urraza AI, Giralt M, Gonzalez FF, Villarroya F, Perez A, Flores PR, Perez M, Domingo P, Lopez FC. FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). PLoS One. 2021; 16(5):e0252144. DOI:10.1371/journal.pone.0252144. PMID:34019585. IF:3,752.
Vilchez HH, Escudero R, Fernandez M, Murillo O, Aunon A, Rodriguez D, Jover A, del Toro MD, Rico A, Falgueras L, Praena J, Guio L, Iribarren JA, Lora J, Benito N, Morata L, Ramirez A, Riera M, Mur I, Coll P, Crusi X, Soriano A. Prosthetic Shoulder Joint Infection by Cutibacterium acnes: Does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study. Antibiotics-Basel. 2021; 10(5):475. DOI:10.3390/antibiotics10050475. PMID:33919103. IF:5,222.

2017 Scientific Report – Research Group in HIV

Presentación

Principales líneas de investigación

Proyectos sanitarios.
Estudios de mecanismos patogénicos que alteran la distribución de grasa corporal.
Estudio de trastornos metabólicos asociados al tratamiento antirretroviral.
Cambios en la composición corporal.
Nuevos fármacos antirretrovirales.
Riesgo cardiovascular asociado al tratamiento antirretroviral.
Condiciones de comorbilidad asociadas a la infección por VIH-1.
Farmacogenética (toxicocinética).
Meningitis bacteriana.

Retos

Proyectos sanitarios

Continuidad, expansión y consolidación del equipo de atención de pacientes infectados con VIH-1, que actualmente consiste en 3 médicos, 4 investigadores asociados subvencionados (incluyendo un investigador Río Hortega) y 2 enfermeras.
Continuidad en la participación en proyectos multicéntricos (especialmente en la red SIDA, Gesida, Vacher, EuroSIDA y colaboración ART).
Exploración de posibles participaciones en ensayos clínicos con nuevos fármacos antirretrovirales.
Incrementar el número de pacientes con VIH-1 que hacen seguimiento a nuestro Hospital (dada la actual tasa de mortalidad, se requiere un incremento anual de 50 pacientes).
Continuidad con los ensayos clínicos en desarrollo actualmente y con las líneas de investigación clínica básicas.

Mecanismos patogénicos que alteran la distribución de grasa corporal

Estudio del metabolismo en pirimidinas y derivados en la génesis de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.
Desarrollo de un modelo animal (ratón) para lipodistrofia.
Desarrollo de modelos in vitro (cultivos de adipocitos) para estudiar la toxicidad adiposa de los fármacos antirretrovirales.
Estudio de las nuevas manifestaciones del síndrome de lipodistrofia.
Desarrollo de medidas para la concentración de fármacos antirretrovirales en el tejido adiposo.
Exploración del rol de la inflamación en la patogénesis de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.
Metabolismo de la uridina y su rol en la patogénesis de la lipodistrofia.

Trastornos metabólicos asociados al tratamiento antiretroviral

Valoración in vivo de la toxicidad metabólica asociada al tratamiento antirretroviral.
Desarrollo de modelos in vitro (cultivos de adipocitos) para estudiar la toxicidad adiposa de los fármacos antirretrovirales.
Estudio de los factores que contribuyen a la esteatosis hepática en pacientes con tratamiento antirretroviral.
Estudio del rol patogénico del FGF21 en la resistencia a la insulina en pacientes con VIH-1.
Estudio del rol de FABP4 en trastornos metabólicos asociados al tratamiento antirretroviral.

Composición corporal

Definición de la distribución normal de grasa en la población general.
Establecer patrones de distribución anormal de grasa.
Desarrollo de una definición de lipodistrofia asociada a VIH-1 y tratamiento antirretroviral.

Nuevos fármacos antiretrovirales

Ensayos clínicos de nuevos fármacos antirretrovirales (fase II y III).
Potenciación farmacocinética de ritonavir y no ritonavir en fármacos antirretrovirales.

Riesgo cardiovascular asociado al tratamiento antiretroviral

Establecimiento de una cohorte de riesgo cardiovascular multicentro.
Estudio de factores dependientes de tratamiento antirretroviral y no dependientes en cohortes multicentro.
Desarrollo de modelos in vitro (cultivos de adipocitos para estudiar la toxicidad adiposa de los fármacos antirretrovirales.

Condiciones de comorbilidad asociadas a la infección por VIH-1

Estudio del envejecimiento en diferentes tejidos asociados a la infección por VIH-1 y tratamientos antirretrovirales.
Estudio de la fragilidad en pacientes con infección por VIH-1 y el rol de HAART.
Evaluación de la función neurocognitiva en pacientes con infección por VIH-1 con y sin tratamiento antirretroviral.
Participación en estudios multicéntricos de cohorte para determinar la incidencia de comorbilidades específicas (cáncer, hepatitis C, enfermedad cardiovascular, osteogénesis / osteoporosis): EuroSIDA, Colaboración ARTE, Gesida, Vacher, etc.
Tratamiento de la hepatitis C en pacientes con VIH-1 y su pronóstico.

Farmacogenética (toxicocinética)

Rol del polimorfismo enzimático de las rutas de la pirimidina en la patogénesis de lipodistrofia.
Rol del polimorfismo enzimático de las rutas de la pirimidina en la patogénesis de toxicidad clínica (neuropatías, pancreatitis).
Rol del polimorfismo de IL28B en cuidado espontánea de hepatitis C como respuesta a tratamientos antirretrovirales basados en interferón y Ribavirin.

Meningitis bacteriana

Identificación de factores de pronóstico en meningitis bacteriana adulta.
Comunicación con un estudio de cohorte de meningitis bacteriana adulta.
Identificación de factores de huésped intrínseco en la patogénesis y prognosis de meningitis bacteriana adulta y enfermedad meningococal.

Equipo

Coordinación del grupo

DOMINGO PEDROL, PERE FGS
pdomingo@santpau.cat

Miembros

Herrera Bachs, Silvia IR

Millan Revilla, Lucia IR

Muñoz Rodriguez, Jessica IR

Producción científica

Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13212. PMID:34882940. IF:3 (Q3/7D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
Calvet J, Berenguer A, Gay M, Massanella M, Domingo P, Llop M, Sanchez E, Arevalo M, Carrillo J, Albinana N, Arauz G, Orellana C, Delgado JF, Serrano A, Llobell A, Graell E, Garcia M, Moreno M, Galisteo C, Casado E, Navarro N, Gomez A, Garcia S, Rusinol M, Costa E, Clotet B, Vilaseca M, Blanco J, Gratacos J. Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports. 2022; 12(1):640. DOI:10.1038/s41598-021-04683-w. PMID:35022497. IF:4,6 (Q2/3D). Document type: Article.
Castellvi I, Castillo D, Corominas H, Mariscal A, Orozco S, Benito N, Pomar V, Baucells A, Mur I, de la Rosa D, Lobo D, Millan AM, de Sosa NH, Filella D, Matas L, Martinez L, Juarez C, Casademont J, Domingo P. Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study. Frontiers in Medicine. 2022; 9:973918. DOI:10.3389/fmed.2022.973918. PMID:36004366. IF:3,9 (Q2/4D). Document type: Article.
Castro A, Diaz P, Domingo P, Garcia C, Losa JE, Castro A, Vidal N, Aceituno S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6). DOI:10.7399/fh.13038. PMID:36520571. Document type: Article.
Collazos J, Domingo P, Fernandez N, Asensi E, Vilchez H, Lalueza A, Roy E, Blanes R, Raya M, Sanz J, Artero A, Ramos JM, Duenas C, Lamas JL, Asensi V, Valproic Acid COVID GRP. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022; 17(1):e0262777. DOI:10.1371/journal.pone.0262777. PMID:35085321. IF:3,7 (Q2/4D). Document type: Article.
Cozzi A, Peters L, Pelchen A, Neesgaard B, Stephan C, Elbirt D, Brännström J, Paduta D, Trofimova T, Szlavik J, Van V, Pai H, Lundgren J, Harxhi A, Losso M, Kundro M, Schmied B, Karpov I, Vassilenko A, Paduto D, Mitsura VM, Clumeck N, De Wit S, Delforge M, Hadziosmanovic V, Begovac J, Machala L, Jilich D, Gerstoft J, Pedersen C, Sedlacek D, et al. [Domingo P], for the EuroSIDA Study Group. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy. 2022; 19(1):38. DOI:10.1186/s12981-022-00457-0. PMID:35933352. IF:2,2 (Q4/8D). Document type: Article.
De Dios A, Masip M, Pagès N, Riera P, Mateo MG, Del Mar M, Mangues MA, Gomis M. Desarrollo de una intervención mHealth para rediseñar la ruta asistencial de las personas que viven con VIH: Estudio cualitativo. Farmacia Hospitalaria. 2022; 46. DOI:10.7399/fh.13249. PMID:36520560. Document type: Article.
Domingo P, Giralt M, Gavalda A, Blasco A, Delgado A, Gallego JM, Gutierrez MD, Mateo MG, Cereijo R, Domingo JC, Villarroya F, Villarroya J. Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy. 2022; 11(1):2042962. DOI:10.1080/21623945.2022.2042962. PMID:35300561. IF:3,3 (Q3/6D). Document type: Article.
Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderros L, Gallego JM, Gutierrez MD, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine. 2022; 11(3):549. DOI:10.3390/jcm11030549. PMID:35160008. IF:3,9 (Q2/4D). Document type: Article.
Domingo P, Quesada T, Villarroya J, Cairo M, Gutierrez MD, Mateo MG, Mur I, Corbacho N, Domingo JC, Villarroya F, Giralt M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308:120948. DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6,1 (Q1/2D). Document type: Article.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Tellez MJ, Dominguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero A, Santos I, Giner L, Arminanzas C, Montero M, Manzardo C, Cifuentes C, Garcia C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodriguez C, Gaspar G, Perez L, Losa JE, Force L, Veloso S, Martinez E, Jarrin I, De Miguel M, Garcia JG. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV MEDICINE. 2022; 23(7). DOI:10.1111/hiv.13229. PMID:35037379. IF:3 (Q3/7D). Document type: Article.
Franquet T, Domingo P. Pulmonary Infections in People Living with HIV. RADIOLOGIC CLINICS OF NORTH AMERICA. 2022; 60(3). DOI:10.1016/j.rcl.2022.01.008. PMID:35534134. IF:1,9 (Q3/8D). Document type: Review.
Franquet T, Gimenez A, Ketai L, Mazzini S, Rial A, Pomar V, Domingo P. Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. EUROPEAN RADIOLOGY. 2022; 32(7). DOI:10.1007/s00330-022-08580-2. PMID:35226158. IF:5,9 (Q1/2D). Document type: Article.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:2,5 (Q3/6D). Document type: Article.
Garcia C, Cereijo R, Plou C, Gavalda A, Malpique R, Villarroya J, Lopez A, de Zegher F, Ibanez L, Villarroya F. Posterior Cervical Brown Fat and CXCL14 Levels in the First Year of Life: Sex Differences and Association With Adiposity. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022; 107(3). DOI:10.1210/clinem/dgab761. PMID:34677618. IF:5,8 (Q1/3D). Document type: Article.
Garreta E, Prado P, Stanifer ML, Monteil V, Marco A, Ullate A, Moya D, Vilas A, Tarantino C, Romero JP, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo M, González F, Domingo P, Gavaldà A, del Pozo CH, Hasan O, Ventura P, Campistol JM, Prosper F, Mirazimi A, Boulant S, Penninger JM, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabolism. 2022; 34(6). DOI:10.1016/j.cmet.2022.04.009. PMID:35561674. IF:29 (Q1/1D). Document type: Article.
Gavalda A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: An update on actors and actions. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2022; 23(1). DOI:10.1007/s11154-021-09640-6. PMID:33712997. IF:8,2 (Q1/1D). Document type: Review.
Llaurado G, Vlacho B, Wargny M, Ruan Y, Franch J, Domingo P, Gourdy P, Saulnier PJ, Hadjadj S, Wild SH, Rea R, Cariou B, Khunti K, Mauricio D. The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19). Cardiovascular Diabetology. 2022; 21(1):216. DOI:10.1186/s12933-022-01657-8. PMID:36261811. IF:9,3 (Q1/1D). Document type: Article.
Martin R, Reyes J, Bruguera A, Aceitón J, Díaz Y, Moreno S, Domingo P, Burgos J, Tiraboschi JM, Johansen IS, Álvarez H, Miró JM, Casabona J, Llibre JM, PISCIS G. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. Eclinicalmedicine. 2022; 52:101600. DOI:10.1016/j.eclinm.2022.101600. PMID:35958520. IF:15,1 (Q1/1D). Document type: Article.
Masip J, Jorba R, Lopez M, Domingo P, Pacheco YM, Garcia G, Martinez E, Vilades C, Veloso S, Alba V, Olona M, Vidal F, Gomez F, Peraire J, Rull A. Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(15):8071. DOI:10.3390/ijms23158071. PMID:35897644. IF:5,6 (Q1/3D). Document type: Article.
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Foppa CU, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13210. PMID:34889022. IF:3 (Q3/7D). Document type: Article.
Moga E, Lynton E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology. 2022; 13:904686. DOI:10.3389/fimmu.2022.904686. PMID:35833134. IF:7,3 (Q1/3D). Document type: Review.
Munoz J, Millan L. The role of nurses in the prevention of anal cancer in HIV- infected men having sex with men – a focus on papillomavirus vaccination and anal cytology screening. AIDS REVIEWS. 2022; 24(4). DOI:10.24875/AIDSRev.M22000053. PMID:36580603. IF:2,2 (Q4/8D). Document type: Review.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM, PISCIS GRP. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(8). DOI:10.1093/jac/dkac177. PMID:35678461. IF:5,2 (Q1/2D). Document type: Article.
Podzamczer D, Mican R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masia M, Gomez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro A, Bernal E, Vinuesa D, Knobel H, Troya J, Macias J, Montero M, Sanz J, Navarro A, Caicedo A, Fernandez G, Martinez E, Moreno S, SYMTRI I. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3):ofab595. DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4,2 (Q2/4D). Document type: Article.
Reyes D, Lopez J, Moga E, Pla F, Lynton E, Rojas R, Turon J, Querol L, Olive M, Alvarez R, Caballero M, Carbayo A, Vesperinas A, Domingo P, Illa I, Gallardo E, Cortes E. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(4):e200002. DOI:10.1212/NXI.0000000000200002. PMID:35728947. IF:8,8 (Q1/1D). Document type: Article.
Riancho JA, Peris P, González J, Pérez JL, Cannata J, Cano A, Carbonell C, Casado E, Ciria M, Corral L, del Pino J, Del Río LM, Díaz M, Díez A, García A, Gómez C, Gómez de Tejada Romero MJ, Guañabens N, Hawkins F, Jódar E, Malouf J, Martínez Díaz G, Monegal A, Muñoz M, Naves M, Nogues X, Nolla JM, Olmos JM, Peris P, Quesada JM, Rodríguez M, Sosa M, Torrijos A, Valero Díaz de Lamadrid C, SEIOMM Osteoporosis Guidelines Writing G. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1). DOI:10.4321/S1889-836X2022000100002. Document type: Article.
Saumoy M, Sanchez JL, Assoumou L, Gatell JM, Gonzalez A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masia M, Ordonez J, Pozniak A, Martinez E, Podzamczer D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(7). DOI:10.1093/jac/dkac117. PMID:35411401. IF:5,2 (Q1/2D). Document type: Article/Practice guideline.
Spinner CD, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, Stephan CJ, DeGrosky M, Bainbridge V, Zhan J, Dumitrescu TP, Jeffrey JL, Xu JF, Halliday F, Gan JJ, Johnson M, Gartland M, Joshi SR, Lataillade M, Study 208132. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. CLINICAL INFECTIOUS DISEASES. 2022; 75(5). DOI:10.1093/cid/ciab1065. PMID:34996113. IF:11,8 (Q1/1D). Document type: Article.
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6). DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:16,1 (Q1/1D). Document type: Article.
Yeregui E, Masip J, Vilades C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, Garcia G, Negredo E, Olona M, Vidal J, Peraire M, Marti A, Reverte L, Gomez F, Leal M, Vidal F, Peraire J, Rull A. Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4):2202. DOI:10.3390/ijms23042202. PMID:35216318. IF:5,6 (Q1/3D). Document type: Article.

Publicaciones 2021

Alserawan L, Penacoba P, Echevarria S, Castillo D, Ortiz E, Martinez L, Naranjo EM, Domingo P, Castellvi I, Juarez C, Mariscal A. Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics. 2021; 11(11):1998. DOI:10.3390/diagnostics11111998. PMID:34829345. IF:3,992.
Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jablonowska E, Ostergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A, Group ES. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2021; 86(2). DOI:10.1097/QAI.0000000000002541. PMID:33079903. IF:3,771.
Arroyo JA, Julve J, Vlacho B, Corcoy R, Ponte P, Roman E, Navas E, Llaurado G, Franch J, Domingo P, Mauricio D. Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health. 2021; 9:758347. DOI:10.3389/fpubh.2021.758347. PMID:34631653. IF:6,461.
Berenguer J, Borobia AM, Ryan P, Rodriguez J, Bellon JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Mancebo J, MARTIN A. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. THORAX. 2021; 76(9). DOI:10.1136/thoraxjnl-2020-216001. PMID:33632764. IF:9,102.
Brochado O, Martinez I, Berenguer J, Medrano L, Gonzalez J, Jimenez MA, Carrero A, Hontanon V, Navarro J, Guardiola JM, Fernandez A, Resino S, Domingo P, Esteban H. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. JOURNAL OF BIOMEDICAL SCIENCE. 2021; 28(1):23. DOI:10.1186/s12929-021-00718-6. PMID:33785040. IF:12,771.
Camps A, Perez S, Subirana I, Teira R, Estrada V, Domingo P, Degano IR, Marrugat J. Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population. Journal of Personalized Medicine. 2021; 11(11):1085. DOI:10.3390/jpm11111085. PMID:34834438. IF:3,508.
Cereijo R, Quesada T, Gavalda A, Tarasco J, Pellitero S, Reyes M, Puig M, Giralt M, Sanchez D, Villarroya F. The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans. INTERNATIONAL JOURNAL OF OBESITY. 2021; 45(3). DOI:10.1038/s41366-020-00732-y. PMID:33414488. IF:5,551.
Corbacho N, Mur I, Molas ME, Vidal F, Domingo P. The pharmacological management of cardiovascular disease in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(6). DOI:10.1080/14656566.2020.1856075. PMID:33283570. IF:4,103.
Corominas H, Castellvi I, Diaz C, Matas L, de la Rosa D, Mangues MA, Moya P, Pomar V, Benito N, Moga E, Hernandez N, Casademont J, Domingo P. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. MEDICINE. 2021; 100(19):e25923. DOI:10.1097/MD.0000000000025923. PMID:34106658. IF:1,817.
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF:10,190.
Domingo P, Pomar V, Mur I, Castellvi I, Corominas H, de Benito N. Not all COVID-19 pandemic waves are alike. CLINICAL MICROBIOLOGY AND INFECTION. 2021; 27(7). DOI:10.1016/j.cmi.2021.04.005. PMID:33887469. IF:13,310.
Elias MJP, Alejos B, Gutierrez MM, Crespo M, Gil ID, Ribera E, Galindo MJ, Lozano F, Cifre AP, Boix V, Montero M, Sanz J, Lima JD, Palacios R, Moral SDF, Martinez E. Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(4). DOI:10.1093/jac/dkaa547. PMID:33501995. IF:5,758.
Fernández I, de Lazzari E, Inciarte A, Diaz-Brito V, Milinkovic A, Arenas-Pinto A, Etcheverrry F, García F, Leal L; HIV-PEP Group [Domingo P]. Network meta-analysis of post-exposure prophylaxis randomized clinical trials. HIV Medicine. 2021;22(3):218-224. DOI:10.1111/hiv.12964. PMID: 33108035. IF:3,094.
Gonzalez A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martinez E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9). DOI:10.1093/jac/dkab158. PMID:34120186. IF:5,758.
Grau B, Camprubi D, Marti H, Fernandez M, Carreras C, Velasco M, Ferrer E, Muelas M, Jullien S, Barilaro G, Ajanovic S, Vera I, Moreno L, Gonzalez E, Cortes N, Roldan M, Artes A, Mur I, Domingo P, Garcia F, Guinovart C, Munoz J. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021; 22(1):808. DOI:10.1186/s13063-021-05758-9. PMID:34781981. IF:2,728.
Gutierrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachon J, Carratala J, Berenguer J, Arribas JR, Rodriguez J, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Puig M, Mancebo J, Martinez G. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. LANCET INFECTIOUS DISEASES. 2021; 21(6). DOI:10.1016/S1473-3099(21)00019-0. PMID:33636145. IF:71,421.
Gutierrez MD, Mur I, Mateo MG, Vidal F, Domingo P. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(9). DOI:10.1080/14656566.2021.1887140. PMID:33634724. IF:4,103.
Kowalska JD, Pelchen A, Ryom L, Losso MH, Trofimova T, Mitsura VM, Khromova I, Paduta D, Stephan C, Domingo P, Bakowska E, Monforte AD, Oestergaard L, Jablonowska E, Kuznetsova A, Moreno S, Vasylyev M, Pradier C, Battegay M, Vandekerckhove L, Castagna A, Raben D, Mocroft A, EuroSIDA GRP. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. AIDS. 2021; 35(12). DOI:10.1097/QAD.0000000000002954. PMID:34033590. IF:4,632.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Llibre JM, Domingo P, Falco V, Imaz A, Cortes C, Force L, Letang E, Vilaro I, Casabona J, Miro JM, Mur I, Macorigh L. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11). DOI:10.1016/S2352-3018(21)00240-X. PMID:34655549. IF:16,070.
Ortega E, Corcoy R, Gratacos M, Claramunt FXC, Mata M, Puig R, Real J, Vlacho B, Castelblanco E, Domingo P, Khunti K, Franch J, Mauricio D. Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open. 2021; 11(7):e051237. DOI:10.1136/bmjopen-2021-051237. PMID:34301668. IF:3,006.
Palacio J, Reyes JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaro I, Borras FH, Falco V, Riera M, Domingo P, de Lazzari E, Miro JM, Casabona J, Gurgui M, Hernandez J. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC PUBLIC HEALTH. 2021; 21(1):1596. DOI:10.1186/s12889-021-11613-y. PMID:34454444. IF:4,135.
Reyes M, Gonzalez L, Ibeas K, Cereijo R, Taxeras SD, Pellitero S, Martinez E, Tarasco J, Moreno P, Malagon P, Higueras C, Soria A, Puig M, Villarroya F, Serra D, Herrero L, Sanchez D. White adipose tissue-infiltrated CD11b+myeloid cells are a source of S100A4, a new potential marker of hepatic damage. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2021; 184(4). DOI:10.1530/EJE-20-1130. PMID:33524007. IF:6,558.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martinez E, DOLAM GRP. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8). PMID:34358497. IF:16,070.
Shankar M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez A, Feuth T, Garcia F, Garcia R, Gonzalez I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, et al. [Pomar V, Benito N]. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2021; 326(6). DOI:10.1001/jama.2021.11330. PMID:34228774. IF:157,335.
Teira R, Diaz H, Aragao F, Marguet S, de la Fuente B, Munoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martinez E, Geijo P, Estrada V, Garcia J, Sepulveda MA, Berenguer J. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS One. 2021; 16(4):e0249515. DOI:10.1371/journal.pone.0249515. PMID:33831047. IF:3,752.
Teira R, Diaz H, Aragao F, Munoz J, Galindo P, Merino M, de la Fuente B, Sepulveda MA, Domingo P, Garcia J, Castano M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martinez E, Estrada V, Montero M, Berenguer J, Espinosa N. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research & Clinical Practice. 2021; 22(3). DOI:10.1080/25787489.2021.1955197. PMID:34410219. IF:1,676.
Urraza AI, Giralt M, Gonzalez FF, Villarroya F, Perez A, Flores PR, Perez M, Domingo P, Lopez FC. FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). PLoS One. 2021; 16(5):e0252144. DOI:10.1371/journal.pone.0252144. PMID:34019585. IF:3,752.
Vilchez HH, Escudero R, Fernandez M, Murillo O, Aunon A, Rodriguez D, Jover A, del Toro MD, Rico A, Falgueras L, Praena J, Guio L, Iribarren JA, Lora J, Benito N, Morata L, Ramirez A, Riera M, Mur I, Coll P, Crusi X, Soriano A. Prosthetic Shoulder Joint Infection by Cutibacterium acnes: Does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study. Antibiotics-Basel. 2021; 10(5):475. DOI:10.3390/antibiotics10050475. PMID:33919103. IF:5,222.

GRUPOS ASOCIADOS

HIV y AIDS

Principales líneas de investigación

Retos

Proyectos sanitarios

Mecanismos patogénicos que alteran la distribución de grasa corporal

Trastornos metabólicos asociados al tratamiento antiretroviral

Composición corporal

Nuevos fármacos antiretrovirales

Riesgo cardiovascular asociado al tratamiento antiretroviral

Condiciones de comorbilidad asociadas a la infección por VIH-1

Farmacogenética (toxicocinética)

Meningitis bacteriana

Coordinación del grupo

Miembros

Publicaciones 2024

Publicaciones 2023

Publicaciones 2022

Publicaciones 2021

Principales líneas de investigación

Retos

Proyectos sanitarios

Mecanismos patogénicos que alteran la distribución de grasa corporal

Trastornos metabólicos asociados al tratamiento antiretroviral

Composición corporal

Nuevos fármacos antiretrovirales

Riesgo cardiovascular asociado al tratamiento antiretroviral

Condiciones de comorbilidad asociadas a la infección por VIH-1

Farmacogenética (toxicocinética)

Meningitis bacteriana

Coordinación del grupo

Miembros

Publicaciones 2024

Publicaciones 2023

Publicaciones 2022

Publicaciones 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau